

Sensitization of Gram-Negative Bacteria to Aminoglycosides with 2-aminoimidazole Adjuvants

Ashley N. Crotteau, Veronica B. Hubble, Santiana A. Marrujo, Anne E. Mattingly, Roberta J. Melander, and Christian Melander*

Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA; acrottea@nd.edu (A.C.)

*Correspondence: cmelande@nd.edu

Table of Contents

Biological Data.....	2
Table S1. Minimum inhibitory concentration data of initial compounds tested against AB5075 and AB19606.	2
Figure S1. Structures of additional analogs tested in combination with TOB against <i>A. baumannii</i>	2
Table S2. Additional compound MICs against AB5075 and AB19606.....	3
Table S3. TOB MICs in combination with all additional analogs against AB5075 and AB19606.....	5
Table S4. Compound MICs against a panel of <i>K. pneumoniae</i> and <i>E. coli</i> strains.....	6
Table S5. TOB MICs in the presence of 20 mM MgCl ₂	6
Table S6. Tobramycin MICs in (TOB only) evolved AB5075.....	6
Table S7. TOB potentiation in the presence and absence of compound 1 in AB5075 serially passaged in TOB + 1.	7

Biological Data

Table S1. Minimum inhibitory concentration data of initial compounds tested against AB5075 and AB19606.

Compound	MIC (μM) against AB5075	MIC (μM) against AB19606
1	100	100
2	100	100
3	50	100
4	>200	>200
5	25	50




Figure S1. Structures of additional analogs tested in combination with TOB against *A. baumannii*.

Table S2. Additional compound MICs against AB5075 and AB19606.

Compound	MIC (μ M) against AB5075	MIC (μ M) against AB19606
6	200	100
7	100	50
8	200	200
9	100	>200
10	100	>200
11	200	100
12	200	200
13	100	100
14	>200	>200
15	50	50
16	200	100
17	>200	>200
18	100	50
19	>200	100
20	>200	>200
21	>200	>200
22	>200	>200
23	>200	>200
24	>200	>200
25	>200	>200
26	100	50
27	>200	>200
28	>200	>200
39	>200	>200
30	>200	>200
31	>200	>200
32	>200	>200
33	>200	>200
34	>200	>200
35	>200	>200
36	50	50
37	>200	>200
38	200	100
39	>200	>200
40	>200	>200
41	100	200

42	>200	>200
43	>200	>200
44	>200	>200
45	>200	>200

Table S3. TOB MICs in combination with all additional analogs against AB5075 and AB19606.

Compound	AB5075		AB19606	
	Concentration tested (μ M)	TOB MIC (μ g/mL) [fold-reduction]	Concentration tested (μ M)	TOB MIC (μ g/mL) [fold-reduction]
		128		4
13	30	16 [8]	30	1 [4]
14	60	16 [8]	60	2 [2]
15	15	8 [16]	15	2 [2]
16	60	8 [16]	30	1 [4]
17	10	128 [0]	10	2 [2]
18	30	32 [4]	15	>4 [0]
19	60	8 [16]	30	0.5 [8]
20	60	128 [0]	60	>4 [0]
21	60	64 [2]	60	2 [2]
22	60	32 [4]	60	4 [0]
23	60	128 [0]	60	>4 [0]
24	60	128 [0]	60	>4 [0]
25	60	128 [0]	60	4 [0]
26	30	64 [2]	15	2 [2]
27	60	64 [2]	60	>4 [0]
28	60	128 [0]	60	>4 [0]
29	60	64 [2]	60	2 [2]
30	60	128 [0]	60	>4 [0]
31	60	128 [0]	60	4 [0]
32	60	64 [2]	60	1 [4]
33	60	32 [4]	60	1 [4]
34	60	128 [0]	60	4 [0]
35	60	32 [4]	60	2 [2]
36	15	128 [0]	15	2 [2]
37	60	64 [2]	60	4 [0]
38	60	32 [4]	30	4 [0]
39	60	128 [0]	60	>4 [0]
40	60	64 [2]	60	>4 [0]
41	30	32 [4]	60	2 [2]
42	60	128 [0]	60	>4 [0]
43	60	64 [2]	60	2 [2]
44	60	128 [0]	60	4 [0]
45	60	128 [0]	60	4 [0]

Table S4. Compound MICs against a panel of *K. pneumoniae* and *E. coli* strains.

Strain	MIC of 1 (μ M)	MIC of 3 (μ M)	MIC of 5 (μ M)	MIC of 10 (μ M)	MIC of 11 (μ M)	MIC of 12 (μ M)
KP1705	50	50	50	200	>200	>200
KP43816	50	50	50	100	>200	*n.d.
EC197	12.5	25	25	50	200	50
EC199	25	25	25	50	>200	50

*n.d. = not determined

Table S5. TOB MICs in the presence of 20 mM MgCl₂.

Compound	AB5075			AB19606		
	Concentration tested (μ M)	TOB MIC (μ g/mL)	TOB MIC (μ g/mL) + 20 mM MgCl ₂	Concentration tested (μ M)	TOB MIC (μ g/mL)	TOB MIC (μ g/mL) + 20 mM MgCl ₂
		128	512		4	128
1	30	2	128			
3				30	0.5	64

Table S6. Tobramycin MICs in (TOB only) evolved AB5075.

TOB (μ g/mL)	TOB (μ g/mL) + 1 (15 μ M)
2048	2048

Table S7. TOB potentiation in the presence and absence of compound **1** in AB5075 serially passaged in TOB + **1**.

	Concentration of compound 1 (μM)	TOB MIC ($\mu\text{g/mL}$)
Day 0	0	128
	15	16
Day 2	0	256
	15	64
Day 4	0	1024
	15	512
Day 6	0	1024
	15	1024
Day 8	0	2048
	15	2048